Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Dec;81(6):349-72.
doi: 10.1046/j.1365-2613.2000.00186.x.

Metabolic cardiomyopathies

B Guertl  1 , C Noehammer, G Hoefler
Affiliations
Review

Metabolic cardiomyopathies

B Guertl et al. Int J Exp Pathol. 2000 Dec.

Abstract

The energy needed by cardiac muscle to maintain proper function is supplied by adenosine Ariphosphate primarily (ATP) production through breakdown of fatty acids. Metabolic cardiomyopathies can be caused by disturbances in metabolism, for example diabetes mellitus, hypertrophy and heart failure or alcoholic cardiomyopathy. Deficiency in enzymes of the mitochondrial beta-oxidation show a varying degree of cardiac manifestation. Aberrations of mitochondrial DNA lead to a wide variety of cardiac disorders, without any obvious correlation between genotype and phenotype. A completely different pathogenetic model comprises cardiac manifestation of systemic metabolic diseases caused by deficiencies of various enzymes in a variety of metabolic pathways. Examples of these disorders are glycogen storage diseases (e.g. glycogenosis type II and III), lysosomal storage diseases (e.g. Niemann-Pick disease, Gaucher disease, I-cell disease, various types of mucopolysaccharidoses, GM1 gangliosidosis, galactosialidosis, carbohydrate-deficient glycoprotein syndromes and Sandhoff's disease). There are some systemic diseases which can also affect the heart, for example triosephosphate isomerase deficiency, hereditary haemochromatosis, CD 36 defect or propionic acidaemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Transport of long-chain free fatty acids into mitochondria using carnitine and the responsible enzymes.
Figure 2
Figure 2
Mitochondrial β-oxidation of free fatty acids.
Figure 3
Figure 3
The LCHAD enzyme complex with its subunits.
Figure 4
Figure 4
Diagram of the OXPHOS-system.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams RJ, Cohen DW, Gupte S, et al. In vitro effects of palmitylcarnitine on cardiac plasma membrane Na+, K+-ATPase, and sarcoplasmic reticulum Ca2+-ATPase and Ca2+ transport. J. Biol. Chem. 1979;254:12404–12410. - PubMed
    1. Alexander CS, Forsyth GW, Nagawasa HT, Kohlhoff JG. Alcoholic cardiomyopathy in mice: Myocardial glycogen, lipids and certain enzymes. J. Mol. Cell. Cardiol. 1977a;9:235–245. - PubMed
    1. Alexander CS, Sekhri KK, Nagawasa HT. Alcoholic cardiomyopathy in mice, myocardial glycogen, lipids and certain enzymes. J. Mol. Cell. Cardiol. 1977b;9:247–254. - PubMed
    1. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 1994;267:H742–H750. - PubMed
    1. Andresen BS, Olpin S, Poorthuis BH J M, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am. J. Hum. Genet. 1999;64:479–494. - PMC - PubMed

Publication types

MeSH terms